Sangamo Therapeutics, Inc. (LON:0R1D)
0.7819
-0.0426 (-5.17%)
At close: Apr 25, 2025
Sangamo Therapeutics Revenue
In the year 2024, Sangamo Therapeutics had annual revenue of $57.80M USD, down -67.20%. Sangamo Therapeutics had revenue of $7.55M in the quarter ending December 31, 2024, with 269.78% growth.
Revenue
$57.80M
Revenue Growth
-67.20%
P/S Ratio
2.88
Revenue / Employee
$315.85K
Employees
183
Market Cap
132.87M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57.80M | -118.43M | -67.20% |
Dec 31, 2023 | 176.23M | 64.93M | 58.34% |
Dec 31, 2022 | 111.30M | 598.00K | 0.54% |
Dec 31, 2021 | 110.70M | -7.49M | -6.34% |
Dec 31, 2020 | 118.19M | 15.76M | 15.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Sangamo Therapeutics News
- 23 days ago - Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal - Seeking Alpha
- 23 days ago - Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga
- 23 days ago - RH, Five Below, Sangamo, Bank Of America, Tesla: Why These 5 Stocks Are On Investors' Radars Amid Trump Tariff Meltdown - Benzinga
- 24 days ago - Sangamo Therapeutics (SGMO) Signs Major Licensing Deal with Eli Lilly - GuruFocus
- 24 days ago - Eli Lilly to leverage Sangamo capsid technology for CNS disease therapies - Seeking Alpha
- 24 days ago - Sangamo Therapeutics Stock Surges After The Bell: What's Going On? - Benzinga
- 24 days ago - Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Business Wire
- 5 weeks ago - Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - GuruFocus